Genpharmasec MD, chairman, board of directors and AGM
BSE: 531592Commercial Services & SuppliesSmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹1.02.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹55 Cr3,222nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 21 May 2026
- 0.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- −1.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 21 May 2026
- 0.50
- Volume, BSEVolume. Shares traded on the last trading day.
- 4,22,891
Genpharmasec board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonSOHAN CHATURVEDI
6 directors3 independent1 executive2 non-executive
- RAJESH SADHWANINon-executive · joined Jan 2019 · 1 listed board · 2 committee seats
- SNEHA SADHWANINon-executive · joined Jan 2019 · 1 listed board
- SOHAN CHATURVEDI · ChairpersonExecutive · joined Apr 2024 · 26 months as independent · 2 listed boards · 1 as independent · 2 committee seats, 2 as chair
- SIDDHESH SHENDEIndependent · joined Jul 2022 · 47 months as independent · 2 listed boards · 2 as independent · 4 committee seats
- SACHIN APHANDKARIndependent · joined Mar 2020 · reappointed Nov 2022 · 44 months as independent · 1 listed board · 1 as independent · 2 committee seats
- MAYUR BHATTIndependent · joined Nov 2022 · 44 months as independent · 2 listed boards · 2 as independent · 4 committee seats, 4 as chair
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 27 Jun 20265 of 6 present3 independent · 36 days in between
- 21 May 20264 of 6 present3 independent · 54 days in between
- 27 Mar 20264 of 6 present1 independent · 45 days in between
- 9 Feb 20264 of 6 present3 independent
Audit Committee
Chair MAYUR BHATT
SIDDHESH SHENDE, SACHIN APHANDKAR, RAJESH SADHWANI
- 21 May 20263 of 4 present3 independent · 100 days in between
- 9 Feb 20263 of 4 present3 independent
Nomination and remuneration committee
Chair SACHIN APHANDKAR
SIDDHESH SHENDE, MAYUR BHATT, RAJESH SADHWANI
- 7 May 20264 of 4 present3 independent
Stakeholders Relationship Committee
Chair MAYUR BHATT
SIDDHESH SHENDE, SACHIN APHANDKAR, RAJESH SADHWANI
- 7 May 20264 of 4 present3 independent
- 9 Feb 20263 of 4 present3 independent
Corporate Social Responsibility Committee
Chair SIDDHESH SHENDE
MAYUR BHATT, SOHAN CHATURVEDI
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Bilimoria Mehta & Co.Peer-review certificate valid to Jun 2027
1 earlier auditor
- Abhishek S Tiwari & AssociatesNamed in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Genpharmasec AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Genpharmasec share news and announcements
Annual general meeting, 29 Sep 2026
1,01,409 shareholders on the register on 22 Sep 2026; present: 2 promoters and 34 others; votes counted by Jaymin Modi / M/s Jaymin Modi & Co..The company's voting result (opens in a new tab)
To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended March 31, 2026 together with the Reports of the Board of Directors' and Auditors' thereon.MoreLess
Ordinary99.99% for0.01% againstAgainst: promoters 0.00% · other public 0.04%
Turnout: all 36.85% · promoters 100.00% · other public 7.06%
- To receive, consider and adopt the audited consolidated financial statements of the Company for the financial year ended March 31, 2026 together with the Report of Auditors' thereon:Ordinary99.99% for0.01% against
Against: promoters 0.00% · other public 0.04%
Turnout: all 36.85% · promoters 100.00% · other public 7.06%
- To appoint a director, in the place of Mr. Sohan Chaturvedi (DIN: 09629728) who retires by rotation and being eligible, offers himself for re-appointment.Ordinary99.99% for0.01% against
Against: promoters 0.00% · other public 0.05%
Turnout: all 36.85% · promoters 100.00% · other public 7.06%
- Re-appointment of Mr. Sohan Chaturvedi (DIN:-09629728), as Whole-Time Director of the Company for a period of 3 (Three) Years.Special99.99% for0.01% against
Against: promoters 0.00% · other public 0.05%
Turnout: all 36.85% · promoters 100.00% · other public 7.06%
- Approval for providing loans, guarantees, or security under Section 185 of the Companies Act, 2013.Special100.00% for0.00% against
Against: promoters 0.00% · other public 0.00%
Turnout: all 68.91% · promoters 100.00% · other public 54.24%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2026. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Rights IssuesFeb 2024 | 48.45 | To acquire Equity Shares from existing shareholders of Derren Healthcare Private Limited and making it subsidiary Company. | 14.44 | 14.44 | No |
| Rights IssuesFeb 2024 | 48.45 | To repay or prepay, in Full or in part, of certain Borrowings availed by our Company. | 5.88 | 2.56 | No |
| Rights IssuesFeb 2024 | 48.45 | To part finance the working capital of the Company. | 16.50 | 16.50 | No |
| Rights IssuesFeb 2024 | 48.45 | To Meet General corporate purposes. | 11.38 | 11.38 | No |
| Rights IssuesFeb 2024 | 48.45 | To meet the expenses of the Issue. | 0.25 | 0.25 | No |